Phase 1 N=27 CampETEC Hyperimmune Bovine Colostrum (HBC)
Healthy Volunteer
Primary: Incidence of Adverse Events — 1; 1; 0; 1 events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 LMN-101 in a Campylobacter Human Challenge Model
Campylobacter Infections
Primary: Number of Participants With Solicited or Unsolicited Adverse Events — 15; 16; 17; 16 Participants
Phase 3 N=30 Efficacy of Rifaximin in Preventing Campylobacteriosis
Dysentery · Diarrhea · Enteric Campylobacteriosis
Primary: Campylobacteriosis — 13; 11 Participants
Phase 1 N=48 Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea
Campylobacter Infection
Primary: Safety: Presence of Related/Not Related Local and/or Systemic Reactogenicity (Adverse Events) — 10; 17; 10; 29 Adverse Events
N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
N/A N=67 Epidemiology Non-cholera Vibrio Infections
Vibrio Infections
Primary: Number of Participants With Diagnosed Non-cholerae or Non-O1/O139 Vibrio Infection — 20; 7; 2; 18 Participants
Phase 3 N=259 Antibiotic Safety (SCAMP)
Complicated Intra Abdominal Infections
Primary: Death — 5; 5; 7; 1 Participants
Phase 4 N=200 Ciprofloxacin for Prevention of BK Infection
BK Virus Infection
Primary: Number of Patients Developing BK Infection at 6 Months Post-transplant — 25; 5 Participants
N/A N=3,153 COMBACTE-CDI Understanding the Burden of C. Difficile Infection
Clostridium Difficile Infection
Primary: The Number of Cases of CDI — 103; 0 Participants
Phase 4 N=232 Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection
Helicobacter Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 92; 95 participants
Phase 1 N=30 Study of Efficacy and Safety of ABO809 in Healthy Participants
Cryptosporidium Infection, Cryptosporidiosis
Primary: Percentage of Participants With Cryptosporidium Infection From 72 Hours to 10 Days Post ABO809 Oral Administration — 50; 57.1; 60.0 percentage of participants
Phase 1 N=59 Safety and Immunogenicity of CJCV2 With and Without ALFQ
Campylobacter Infection
Primary: Number and Percentage of Participants With Solicited Local Adverse Events (AEs) Through 7 Days After Each Study Vaccination — 4; 9; 2; 10 Participants
N/A N=70 Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients
Helicobacter Pylori Infection
Primary: Eradication of H Pylori Infection 4 Weeks After Completion of Therapy — 23; 26 participants
Phase 3 N=92 Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin
Recurrent Clostridium Difficile Infection · Primary Clostridium Difficile Infection
Primary: Global Absence of Diarrhea Due to Clostridiodes Difficile 8 Weeks After the Start of the Treatment — 4; 9 Participants — p=0.228
N/A N=983 Probiotics and Infections in Conscripts in Military Service
Respiratory Tract Infections · Gastrointestinal Diseases · Asthma Exacerbations
Primary: Number of Sick Days — p=< 0.05
Phase 2 N=210 Study of CB-183,315 in Participants With Clostridium Difficile Infection
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment — 61; 58; 59 participants
N/A N=23 Pre-Study of Wild Type Enterotoxigenic E. Coli (ETEC) Strain for Verification of a Planned Challenge Dose
ETEC Diarrhea
Primary: Number of Participants With Moderate and Severe Diarrhea — 17 participants moderate or severe diarrea